We are live on ! Find out more
OA

Oak Associates Portfolio holdings

AUM $1.49B
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
+11.98%
1 Year Est. Return
+34.25%
3 Year Est. Return
+111.6%
5 Year Est. Return
+123.41%
10 Year Est. Return
+571.62%
AUM
$1.25B
AUM Growth
+$34.5M
Cap. Flow
-$87.4M
Cap. Flow %
-6.99%
Top 10 Hldgs %
45.53%
Holding
136
New
1
Increased
21
Reduced
59
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
CVS icon
CVS Health
CVS
+$228K
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$184K
4
SNPS icon
Synopsys
SNPS
+$29.8K
5
MSFT icon
Microsoft
MSFT
+$28.8K

Top Sells

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$6.32M
2
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.86M
3
KLAC icon
KLA
KLAC
+$5.4M
4
LOW icon
Lowe's Companies
LOW
+$4.44M
5
SCHW
Charles Schwab
SCHW
+$4.37M

Sector Composition

Rank Sector Weight
1 Technology 45.76%
2 Healthcare 15.36%
3 Communication Services 14.06%
4 Consumer Discretionary 11.65%
5 Financials 10.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALC icon
26
Alcon
ALC
$33.1B
$13.9M 1.11%
168,938
-37,148
-18% -$2.84M
CB icon
27
Chubb
CB
$140B
$13.5M 1.08%
70,291
-16,809
-19% -$3.29M
MA icon
28
Mastercard
MA
$477B
$13M 1.04%
32,959
+37
+0.1% +$13.9K
ZBH icon
29
Zimmer Biomet
ZBH
$17.7B
$12.8M 1.02%
87,822
-17,658
-17% -$2.4M
MCK icon
30
McKesson
MCK
$98.5B
$12.4M 0.99%
29,025
-775
-3% -$298K
AMD icon
31
Advanced Micro Devices
AMD
$851B
$12.2M 0.98%
107,473
+12
+0% +$1.25K
DOX icon
32
Amdocs
DOX
$5.53B
$12M 0.96%
121,509
-3,030
-2% -$285K
PFE icon
33
Pfizer
PFE
$140B
$11.7M 0.93%
318,420
-2,794
-0.9% -$109K
CI icon
34
Cigna
CI
$76.6B
$11.1M 0.89%
39,592
-5
-0% -$1.3K
MCHP icon
35
Microchip Technology
MCHP
$42.8B
$11.1M 0.88%
123,394
+110
+0.1% +$8.68K
GPN icon
36
Global Payments
GPN
$22.1B
$10.2M 0.82%
103,881
+78
+0.1% +$8.02K
QRVO icon
37
Qorvo
QRVO
$7.63B
$10.2M 0.82%
100,264
+142
+0.1% +$13.6K
CTSH icon
38
Cognizant
CTSH
$21.5B
$9.66M 0.77%
147,947
-35,476
-19% -$2.2M
LMT icon
39
Lockheed Martin
LMT
$134B
$8.03M 0.64%
17,447
+17
+0.1% +$7.89K
APH icon
40
Amphenol
APH
$188B
$7.91M 0.63%
186,196
+24
+0% +$932
CHKP icon
41
Check Point Software Technologies
CHKP
$13.3B
$7.43M 0.59%
59,151
+8
+0% +$1.01K
REGN icon
42
Regeneron Pharmaceuticals
REGN
$68.8B
$7.04M 0.56%
9,791
-2
-0% -$1.54K
GILD icon
43
Gilead Sciences
GILD
$161B
$6.69M 0.54%
86,857
-31,868
-27% -$2.54M
INTC icon
44
Intel
INTC
$466B
$5.75M 0.46%
172,050
+119
+0.1% +$3.74K
PAYX icon
45
Paychex
PAYX
$40.4B
$5.28M 0.42%
47,154
-2,965
-6% -$324K
AIZ icon
46
Assurant
AIZ
$13.7B
$5.26M 0.42%
41,841
-710
-2% -$88.4K
DIOD icon
47
Diodes
DIOD
$4B
$5.04M 0.4%
54,473
BNY
48
Bank of New York Mellon
BNY
$108B
$4.97M 0.4%
111,625
-4,970
-4% -$213K
ISRG icon
49
Intuitive Surgical
ISRG
$121B
$4.48M 0.36%
13,088
-810
-6% -$245K
KLIC icon
50
Kulicke & Soffa
KLIC
$5.3B
$4.41M 0.35%
74,140
-5,063
-6% -$261K

Similar funds

Oak Associates's Q2 2023 Portfolio in Review

As of Q2 2023, Oak Associates held 136 positions worth $1.25B, up 2.8% from $1.22B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Oak Associates withdrew a net $87.4M in Q2 2023, closing 5 positions and reducing 59 holdings. Its most notable exit was Ubiquiti, an estimated $1.54M position sold in full.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 45% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Oak Associates opened a new position in Incyte worth $1.72M.

  • Oak Associates's largest Q2 2023 buy was Incyte: 27,651 shares worth $1.72M.
  • Oak Associates added most to CVS Health in Q2 2023, an estimated $228K increase.
  • Oak Associates's biggest Q2 2023 reduction was Amazon, cutting an estimated $6.32M.
  • Oak Associates fully exited Ubiquiti in Q2 2023, selling an estimated $1.54M.
  • Oak Associates's ten largest holdings make up 46% of its $1.25B portfolio in Q2 2023.
  • Oak Associates opened 1 new position and closed 5 in Q2 2023.
  • Oak Associates's portfolio value rose 2.8% quarter-over-quarter to $1.25B.

Based on Oak Associates's 13F filing for Q2 2023, filed 11 Aug 2023.